Aptamers, composed of single-stranded DNA or RNA oligonucleotides that interact with target molecules through a specific three-dimensional structure, are selected from pools of combinatorial oligonucleotide libraries. With their high specificity and affinity for target proteins, ease of synthesis and modification, and low immunogenicity and toxicity, aptamers are considered to be attractive molecules for development as anticancer therapeutics. Two aptamers - one targeting nucleolin and a second targeting CXCL12 - are currently undergoing clinical trials for treating cancer patients, and many more are under study. In this mini-review, we present the current clinical status of aptamers and aptamer-based cancer therapeutics. We also discuss advantages, limitations, and prospects for aptamers as cancer therapeutics.
Korean Society for Biochemistry and Molecular Biology. All Rights Reserved. The Korean Federation of Science and Technology Societies 801, 22, Teheran-ro 7Gil, Gangnam-gu, Seoul 06130, South Korea Tel) 82-2-508-7434 Fax) 82-2-508-7578 e-mail) email@example.com Powered by INFOrang.co., Ltd